CAS 1310726-60-3

Upadacitinib

Description:

Upadacitinib is a selective Janus kinase (JAK) inhibitor primarily used in the treatment of autoimmune diseases, such as rheumatoid arthritis. It works by modulating the immune response, thereby reducing inflammation and alleviating symptoms associated with these conditions. The chemical structure of Upadacitinib features a pyrrolidine ring and a substituted aniline, contributing to its pharmacological activity. It is typically administered orally and has a favorable pharmacokinetic profile, including good absorption and a relatively long half-life, allowing for once-daily dosing. The substance is known for its efficacy in clinical trials, demonstrating significant improvements in disease activity scores compared to placebo. Upadacitinib is also characterized by its safety profile, with common side effects including upper respiratory infections and headaches. As a small molecule drug, it represents a targeted approach in the management of chronic inflammatory diseases, offering an alternative to traditional therapies. Its development reflects ongoing advancements in precision medicine aimed at improving patient outcomes in autoimmune disorders.

Formula: C₁₇H₁₉F₃N₆O

InChI: InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1

InChI key: InChIKey=WYQFJHHDOKWSHR-MNOVXSKESA-N

SMILES: C(C)[C@H]1[C@@H](C=2N3C4=C(N=CC3=NC2)NC=C4)CN(C(NCC(F)(F)F)=O)C1

Synonyms:

• 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-
• (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide
• Upadacitinib
• ABT 494
• rel-(-)-(3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
• Upadacitinib (ABT-494)
• ABT-494; ABT494; ABT 494
• (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, Upadacitinib
• (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
• CS-2730
• ABT-494(Upadacitinib) free base
• benzyl (4S)-3-(N-(ethoxycarbonyl)-N-(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)glycyl)-4-ethylpyrrolidine-1-carboxylate
• Upadacitinib (Rinvoq)

Upadacitinib

CAS: 1310726-60-3

Formula: C₁₇H₁₉F₃N₆O

Purity: 99%

Color and Shape: Solid

Molecular weight: 380.3676

Ref: IN-DA01E0UI

Upadacitinib

CAS: 1310726-60-3

Upadacitinib

Purity: ≥98%

Molecular weight: 380.37g/mol

Ref: 54-BUP15134

Upadacitinib-15N-d2

CAS: 1310726-60-3

Formula: C₁₇H₁₇D₂F₃N₅₁₅NO

Molecular weight: 383.38

Ref: 4Z-U-103020

Upadacitinib

CAS: 1310726-60-3

Formula: C₁₇H₁₉F₃N₆O

Color and Shape: Off-White Solid

Molecular weight: 380.38

Ref: 4Z-U-103001

(3S,4R)-3-Ethyl-4-(3H-Imidazo[1,2-A]Pyrrolo[2,3-E]Pyrazin-8-Yl)-N-(2,2,2-Trifluoroethyl)Pyrrolidine-1-Carboxamide

CAS: 1310726-60-3

(3S,4R)-3-Ethyl-4-(3H-Imidazo[1,2-A]Pyrrolo[2,3-E]Pyrazin-8-Yl)-N-(2,2,2-Trifluoroethyl)Pyrrolidine-1-Carboxamide

Purity: 99%

Molecular weight: 380.37g/mol

Ref: 54-PC108649

Upadacitinib

CAS: 1310726-60-3

Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.

Formula: C₁₇H₁₉F₃N₆O

Purity: 98.96% - 99.94%

Color and Shape: Solid

Molecular weight: 380.37

Ref: TM-T7503

Upadacitinib Tartrate

CAS: 1310726-60-3

Formula: C₁₇H₁₉F₃N₆O·C₄H₆O₆

Molecular weight: 380.38 150.09

Ref: 4Z-U-103002

Upadacitinib-d5

CAS: 1310726-60-3

Formula: C₁₇H₁₄D₅F₃N₆O

Molecular weight: 385.41

Ref: 4Z-U-103021

Upadacitinib

CAS: 1310726-60-3

Purity: 99%

Molecular weight: 380.157

Ref: 10-F797290

Upadacitinib-D2,15N

Controlled Product

CAS: 1310726-60-3

Formula: C₁₇D₂H₁₇F₃₁₅NN₅O

Color and Shape: Neat

Molecular weight: 383.373

Ref: TR-U800077

ABT 494

CAS: 1310726-60-3

Inhibitor of Janus kinase JAK-1

Formula: C₁₇H₁₉F₃N₆O

Purity: Min. 95%

Molecular weight: 380.37 g/mol

Ref: 3D-FA166721